Methods of increasing RDCVF 1 or RDCVF 2 polypeptides in retinal cells
Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed “Rdcvf1,” that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with nonsufferers, antibodies which recognize this protein, and methods for diagnosing such conditions.
1. A method of increasing the amount of Rod-Derived Cone Viability Factor (RDCVF) 1 polypeptide or RDCVF 2 polypeptide in the retinal cells of a subject suffering from a retinal disorder comprising administering a therapeutically effective amount of a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12 and SEQ ID NO:14, and an acceptable carrier, into the retinal cells of the subject, wherein the administration results in an increase of RDCVF 1 or RDCVF 2 in the retinal cells of the subject.
2. The method of claim 1 , wherein the retinal disorder is selected from the group consisting of retinitis pigmentosa, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-Kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, and stargardt disease of Usher syndrome.
3. The method of claim 1 , wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO:2.
4. The method of claim 1 , wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO:4.
5. The method of claim 1 , wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO:6.
6. The method of claim 1 , wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO:8.
7. The method of claim 1 , wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO:10.
8. The method of claim 1 , wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO:12.
9. The method of claim 1 , wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO:14.
10. The method of claim 2 , wherein the retinal disorder is retinitis pigmentosa.